Clinical Trials Directory

Trials / Completed

CompletedNCT02820948

Effect of Vitamin E Ointment on Incisional SSI in Colorectal Surgery

Effect of Subcutaneous Sterile Vitamin E Ointment on Incisional Surgical-site Infection Following Elective Laparoscopic Colorectal Cancer Surgery

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
108 (actual)
Sponsor
Hospital General Universitario Elche · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

A prospective, randomized study was performed. The patients were randomized into 2 groups: those patients undergoing subcutaneous vitamin E ointment application (Group 1) and those patients who not (Group 2). Incisional surgical site infection (SSI), microbiological cultures from the infected surgical wounds, postoperative pain and acute phase reactants were investigated.

Detailed description

A prospective, randomized study was performed. The patients were randomized into 2 groups: those patients undergoing a subcutaneous sterile vitamin E acetate ointment application (Group 1) and those patients who did not receive this vitamin E ointment application (Group 2). Before the skin stapling and after the subcutaneous irrigation with normal saline, sterile Vitamin E acetate ointment (FilmeOft, Hulka SRL, Rovigo, Italy) was applied in the subcutaneous tissue; 2 ml were applied in the suprapubic incision and 0.5 ml in the rest of port sites. Incisional SSI, microbiological cultures from the infected surgical wounds, postoperative pain was evaluated 24 hours after surgery by means of a Visual Analogic Scale (VAS), ranging from 0 mm (complete absence of pain) to 100 mm (unbearable pain) and acute phase reactants (white cell count (WBC), fibrinogen and C reactive protein) 48 hours after surgery were investigated.

Conditions

Interventions

TypeNameDescription
DRUGVitamin E ointment applicationBefore the skin stapling and after the subcutaneous irrigation with normal saline, sterile Vitamin E acetate ointment was applied in the subcutaneous tissue; 2 ml were applied in the suprapubic incision and 0.5 ml in the rest of port sites.

Timeline

Start date
2015-01-01
Primary completion
2016-03-01
Completion
2016-03-01
First posted
2016-07-01
Last updated
2016-07-01

Source: ClinicalTrials.gov record NCT02820948. Inclusion in this directory is not an endorsement.